GetTopicDetailResponse(id=6653233eba, topicName=alloHCT, introduction=alloHCT, content=null, image=null, comments=4, allHits=1145, url=https://h5.medsci.cn/topic?id=2337, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=80192, tagList=[TagDto(tagId=80192, tagName=alloHCT)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1778415, encodeId=ac0a1e78415aa, content=<a href='/topic/show?id=6653233eba' target=_blank style='color:#2F92EE;'>#alloHCT#</a>, objectTitle=J Clin Oncol：alloHCT前調(diào)節(jié)化療的強(qiáng)度對(duì)AML患者預(yù)后的影響, objectType=article, longId=185706, objectId=6aa8185e0619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aa8185e0619, replyNumber=0, likeNumber=113, createdTime=2020-01-15, rootId=0, userName=shock_melon, userId=193939204862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aa8185e0619, moduleTitle=J Clin Oncol：alloHCT前調(diào)節(jié)化療的強(qiáng)度對(duì)AML患者預(yù)后的影響, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6aa8185e0619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1778416, encodeId=61c51e78416b6, content=<a href='/topic/show?id=6653233eba' target=_blank style='color:#2F92EE;'>#alloHCT#</a>, objectTitle=Blood：納武單抗用于alloHCT后復(fù)發(fā)的血液惡性腫瘤的療效和安全性, objectType=article, longId=195515, objectId=098c1955156f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=098c1955156f, replyNumber=0, likeNumber=91, createdTime=2020-10-19, rootId=0, userName=shock_melon, userId=193939204862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=098c1955156f, moduleTitle=Blood：納武單抗用于alloHCT后復(fù)發(fā)的血液惡性腫瘤的療效和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=098c1955156f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1778414, encodeId=443e1e7841462, content=<a href='/topic/show?id=6653233eba' target=_blank style='color:#2F92EE;'>#alloHCT#</a>, objectTitle=Blood：alloHCT前進(jìn)行NGS-MRD分析，可較準(zhǔn)確預(yù)測(cè)AML患者預(yù)后, objectType=article, longId=148500, objectId=a6fd14850017, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6fd14850017, replyNumber=0, likeNumber=95, createdTime=2018-12-03, rootId=0, userName=shock_melon, userId=193939204862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6fd14850017, moduleTitle=Blood：alloHCT前進(jìn)行NGS-MRD分析，可較準(zhǔn)確預(yù)測(cè)AML患者預(yù)后, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a6fd14850017)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1778413, encodeId=7f091e78413e9, content=<a href='/topic/show?id=6653233eba' target=_blank style='color:#2F92EE;'>#alloHCT#</a>, objectTitle=Blood :Ibrutinib可否挽救alloHCT后復(fù)發(fā)的CLL患者？, objectType=article, longId=85769, objectId=337785e6950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=337785e6950, replyNumber=0, likeNumber=81, createdTime=2017-06-25, rootId=0, userName=shock_melon, userId=193939204862, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=337785e6950, moduleTitle=Blood :Ibrutinib可否挽救alloHCT后復(fù)發(fā)的CLL患者？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=337785e6950)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
